Oncology Research Training Grant

肿瘤学研究培训补助金

基本信息

  • 批准号:
    10712973
  • 负责人:
  • 金额:
    $ 36.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1980
  • 资助国家:
    美国
  • 起止时间:
    1980-07-01 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Abstract The Oncology Research Training Program (ORTP) has been in existence for 40 years and was developed with the primary goal of preparing physician-trainees (fellows in Adult Medical Oncology) for careers in academic medicine. The rationale for training in oncology research is four fold: (a) Cancer remains one of the leading cause of morbidity and mortality; (b) there is a need to maintain momentum that has been achieved in our fundamental understanding of carcinogenesis, genomics and immunology (c) there is a need to translate progress gained in the laboratory to the development of novel and better strategies for the diagnosis, therapies and prevention of cancer and (d) in the rapidly chaniging health care advances and economics landscape, a critical need for development of tools and policy to determine the most effective and efficient ways to deliver care and measure outcomes in the society. The five Research training themes of the Program are carefully developed to build on the past successes of training academic leaders. It melds emerging aspects of cancer biology, care and policy, is aligned with the investigative interest and expertise of 44 established, extramurally-funded program faculty members, leverages the outstanding resources of the Division of Hematology/Oncology, the Comprehensive Cancer Center (UMCCC), the medical school and other units of the University of Michigan. The research training themes are: (1) Molecular-genetic mechanisms of neoplastic transformation, aberrant signaling, and metastasis, (2) Biomarkers in cancer prevention and therapy; (3) Molecular targets of drug discovery and experimental therapuetics of cancer; (4) Immunological approaches to cancer therapy and (5) Health services research focused on delivery, outcomes, reform and value. The trainees selected for this program will first experience well-defined curriculum and training to the important concepts in the chosen research theme, and then spend 2- 3 years in the relevant laboratory and/ or clinical or health services research environment under the direct supervision of a training program faculty mentor. The trainees will develop skills in: (a) to identify important questions in oncology research (b) develop testable hypotheses that will address the pertinent questions (c) aquire the necessary technical expertise to rigorously test the hypotheses identified; (d) critically evaluate the data generated; (e) develop the necessary skills of written and oral communication to promulgate the conclusions made and (f) develop and compete of peer-reviewed grants. The trainees will have an MD or MD-PhD degree, completed residency training in Internal Medicine and a year of clinical subspecialty training in ADULT medical oncology/hematology. The ultimate goal of the program is to prepare trainees for careers in academic oncology as independent faculty members in schools of medicine at research universities.
摘要 肿瘤学研究培训计划(OLTP)已经存在了40年,并与 培养实习医生(成人医学肿瘤学研究员)从事学术研究的主要目标 药肿瘤学研究培训的理由有四个方面:(a)癌症仍然是导致癌症的主要原因之一, (B)有必要保持我们在基本保健方面取得的势头, (c)需要将在以下方面取得的进展转化为对癌症发生、基因组学和免疫学的认识: 实验室开发新的和更好的战略,用于诊断,治疗和预防 癌症和(d)在迅速变化的卫生保健进步和经济格局中,迫切需要 制定工具和政策,以确定提供护理和措施的最有效和最高效的方式 社会上的成果。该计划的五个研究培训主题是精心制定的,以建立在 过去培养学术带头人的成功经验。它融合了癌症生物学、护理和政策的新兴方面, 与44个已建立的,校外资助的项目教师的调查兴趣和专业知识相一致 成员,利用血液学/肿瘤学部门的优秀资源,综合 癌症中心(UMCCC),医学院和密歇根大学的其他单位。科研训练 主题是:(1)肿瘤转化、异常信号传导和转移的分子遗传机制, (2)癌症预防和治疗中的生物标志物;(3)药物发现和实验的分子靶点 癌症治疗学;(4)癌症治疗的免疫学方法;(5)卫生服务研究 侧重于交付、成果、改革和价值。被选中参加该计划的学员将首先体验 明确的课程和培训的重要概念,在选定的研究主题,然后花2- 3年在相关实验室和/或临床或卫生服务研究环境下,直接 监督培训计划教师导师。受训人员将发展以下方面的技能:(a)确定重要的 肿瘤学研究中的问题(B)开发可验证的假设,以解决相关问题(c) 获得必要的技术专门知识,以严格检验所确定的假设;(d)严格评估 (e)发展必要的书面和口头交流技能,以公布结论 (f)发展和竞争同行评审赠款。受训人员将拥有MD或MD-PhD学位, 完成了内科住院医师培训和一年的ADEMPLEMEDICAL临床专科培训 肿瘤学/血液学。该计划的最终目标是为学员在学术肿瘤学的职业生涯做准备 作为研究型大学医学院的独立教员。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.
  • DOI:
    10.1007/s11523-017-0526-1
  • 发表时间:
    2017-12
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Qin A;Gadgeel S
  • 通讯作者:
    Gadgeel S
A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck.
顺铂和二氯甲氨蝶呤治疗头颈部鳞状细胞癌的 I-II 期试验。
Immunoperoxidase staining of early human melanoma colonies with monoclonal antibodies. A new method for in vitro antigenic-morphologic correlation.
使用单克隆抗体对早期人类黑色素瘤集落进行免疫过氧化物酶染色。
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
在晚期胰腺癌中,卡培他滨和放射治疗之前和之后进行联合化疗。
  • DOI:
    10.1016/j.ijrobp.2005.04.030
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Schneider,BryanJ;Ben-Josef,Edgar;McGinn,CorneliusJ;Chang,AlfredE;Colletti,LisaM;Normolle,DanielP;Hejna,GwenF;Lawrence,TheodoreS;Zalupski,MarkM
  • 通讯作者:
    Zalupski,MarkM
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
  • DOI:
    10.1002/cam4.819
  • 发表时间:
    2016-09
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Qin, Angel;Coffey, David G.;Warren, Edus H.;Ramnath, Nithya
  • 通讯作者:
    Ramnath, Nithya
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qing Li其他文献

Qing Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qing Li', 18)}}的其他基金

The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
  • 批准号:
    10187650
  • 财政年份:
    2020
  • 资助金额:
    $ 36.11万
  • 项目类别:
The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
  • 批准号:
    10454963
  • 财政年份:
    2020
  • 资助金额:
    $ 36.11万
  • 项目类别:
The role of ER associated degradation (ERAD) in hematopoietic stem cells
ER相关降解(ERAD)在造血干细胞中的作用
  • 批准号:
    10649697
  • 财政年份:
    2020
  • 资助金额:
    $ 36.11万
  • 项目类别:
Oncogenic Nras signaling in leukemic stem cell transformation
白血病干细胞转化中的致癌 Nras 信号传导
  • 批准号:
    9028457
  • 财政年份:
    2016
  • 资助金额:
    $ 36.11万
  • 项目类别:
Oncogenic Nras signaling in leukemic stem cell transformation
白血病干细胞转化中的致癌 Nras 信号传导
  • 批准号:
    9234062
  • 财政年份:
    2016
  • 资助金额:
    $ 36.11万
  • 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
  • 批准号:
    7509983
  • 财政年份:
    2008
  • 资助金额:
    $ 36.11万
  • 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
  • 批准号:
    7923173
  • 财政年份:
    2008
  • 资助金额:
    $ 36.11万
  • 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
  • 批准号:
    8332887
  • 财政年份:
    2008
  • 资助金额:
    $ 36.11万
  • 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
  • 批准号:
    7681712
  • 财政年份:
    2008
  • 资助金额:
    $ 36.11万
  • 项目类别:
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
致癌 Ras 在白血病发生和靶向治疗反应中的作用
  • 批准号:
    8116544
  • 财政年份:
    2008
  • 资助金额:
    $ 36.11万
  • 项目类别:

相似海外基金

Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    9749998
  • 财政年份:
    2019
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    7235998
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    8299404
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
UROLOGY ONCOLOGY RESEARCH TRAINING GRANT
泌尿肿瘤学研究培训补助金
  • 批准号:
    2875956
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    6845175
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    7426286
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    8712143
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
UROLOGY ONCOLOGY RESEARCH TRAINING GRANT
泌尿肿瘤学研究培训补助金
  • 批准号:
    6655574
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
UROLOGY ONCOLOGY RESEARCH TRAINING GRANT
泌尿肿瘤学研究培训补助金
  • 批准号:
    6173563
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
Urologic Oncology Research Training Grant
泌尿肿瘤学研究培训补助金
  • 批准号:
    8538759
  • 财政年份:
    1999
  • 资助金额:
    $ 36.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了